TORONTO and MEDELLIN, Colombia, June 19, 2018 /CNW/ - PharmaCielo Ltd. congratulates President-elect Iván Duque Márquez on a successful campaign in the Colombian election.
"President-elect Duque's commitment to the growth and development of new industries such as medicinal cannabis will benefit the country as a whole," said Anthony Wile, CEO of PharmaCielo Ltd.
Federico Cock-Correo, CEO of PharmaCielo Colombia Holdings S.A.S. added "under the leadership of President-elect Duque, we are confident that all parts of our country, including the poorest and most remote, will be given great opportunity to continue to both participate and benefit from this new industry."
Recognizing and thanking the previous government for taking bold steps in launching the medicinal cannabis industry, PharmaCielo noted that as the new government begins to fulfil its mandate to the people of Colombia, the company stands ready to continue to work alongside to help build out the industry on both the domestic and global stage,
"Our nascent industry relies on the leadership of President-elect Iván Duque to help maintain the momentum that has been established over recent years and made Colombia an increasing interest to the international investment community," said Mr. Wile. "We look forward to the future."
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly-owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or "recurring" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company's products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.
For further information: www.PharmaCielo.com; Media Relations: David Gordon, Tel: +1 647 259 3258, [email protected], (Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776, [email protected], Investor Inquiries: Tel: +1 647 560 4640, Toll Free 888 968 8279, [email protected]